Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology

PartnershipENHANZE®Positive

AI Analysis

Summary

Halozyme expanded its global collaboration and license agreement with argenx, adding two additional exclusive targets for subcutaneous formulation development using ENHANZE® technology, increasing argenx's exclusive target access from six to eight.

Outcome Details

Expansion of existing collaboration and license agreement to include two additional exclusive targets, increasing argenx's exclusive access from six to eight targets

Importance:6/10

Sentiment:

0.60

partnershiplicensingcollaboration expansionsubcutaneous formulationsENHANZE technology

Related Companies

$HALO $ARGX

Read the original article

Published by PR Newswire Biotech on October 6, 2026 8:05 PM

Read Original